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Accounting for 30--40%, the diffuse large B‐cell lymphomas (DLBCLs) are a major group of non‐Hodgkin lymphomas (NHL) (Reiter & Klapper, [2008](#bjh16147-bib-0023){ref-type="ref"}; Roman & Smith, [2011](#bjh16147-bib-0025){ref-type="ref"}). In recent years, it has been shown that gene expression patterns of DLBCLs play a critical role for treatment outcome resulting in a sub‐classification of activated B‐cell (ABC) or germinal centre B‐cell (GCB) ‐like DLBCLs (Alizadeh *et al*, [2000](#bjh16147-bib-0002){ref-type="ref"}). A third pattern identifies primary mediastinal B‐cell lymphoma (PMBL). Receiving state‐of‐the‐art treatment with cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone (CHOP regimen) in combination with the anti‐CD20 antibody, rituximab (Pfreundschuh *et al*, [2006](#bjh16147-bib-0021){ref-type="ref"}; Pfreundschuh *et al*, [2008](#bjh16147-bib-0020){ref-type="ref"}), results in differing 3‐year survival rates, with ABC‐like DLBCL having the least favourable and PMBL having the best prognosis (Rosenwald & Staudt, [2003](#bjh16147-bib-0027){ref-type="ref"}; Lenz *et al*, [2008](#bjh16147-bib-0012){ref-type="ref"}; Dunleavy *et al*, [2013](#bjh16147-bib-0007){ref-type="ref"}; Roschewski *et al*, [2014](#bjh16147-bib-0026){ref-type="ref"}). These differences clearly indicate the importance of the transcriptome in DLBCL. The oncogenic programmes in DLBCL also differ and are largely governed by their genetic background. We were the first to draw attention to mutations in *SOCS1* occurring in B‐cell lymphomas (Barth *et al*, [2005](#bjh16147-bib-0003){ref-type="ref"}; Weniger *et al*, [2006](#bjh16147-bib-0033){ref-type="ref"}; Ritz *et al*, [2008](#bjh16147-bib-0024){ref-type="ref"}; Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}), a finding that has since been confirmed by others (Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}). A recent study for driver mutations in 1001 DLBCLs revealed that *SOCS1* mutations are amongst the 15 most frequent mutations, affirming the relevance of *SOCS1* mutations in DLBCL (Reddy *et al*, [2017](#bjh16147-bib-0022){ref-type="ref"}).

*SOCS1* (synonyms include JAB, SSI‐1 and TIP3) was described as a negative regulator of the STAT‐mediated expression of proliferation‐ and survival‐associated genes by interacting with Janus kinases (JAKs) (Endo *et al*, [1997](#bjh16147-bib-0008){ref-type="ref"}; Naka *et al*, [1997](#bjh16147-bib-0017){ref-type="ref"}; Ohya *et al*, [1997](#bjh16147-bib-0018){ref-type="ref"}; Starr *et al*, [1997](#bjh16147-bib-0032){ref-type="ref"}). Mutations in *SOCS1* were shown to be common in PMBL, in both cell line models and primary tumours, and were associated with a delayed degradation of JAK2 (Melzner *et al*, [2005](#bjh16147-bib-0013){ref-type="ref"}; Melzner *et al*, [2006](#bjh16147-bib-0014){ref-type="ref"}; Ritz *et al*, [2008](#bjh16147-bib-0024){ref-type="ref"}). Furthermore, *SOCS1* mutations were identified in 3/5 classical Hodgkin lymphoma (cHL) cell lines and 8/19 patients (Weniger *et al*, [2006](#bjh16147-bib-0033){ref-type="ref"}). This high frequency was confirmed in 64/105 cases of another cHL cohort. Here, classifying the mutations into minor (those that do not alter the length of the encoded protein) and major mutations (indels and/or truncating mutations) were found to be useful as a prognostic factor for early relapse and overall survival (OS) (Lennerz *et al*, [2015](#bjh16147-bib-0011){ref-type="ref"}). cHL patients harbouring tumour cells with major mutations in *SOCS1* had a significantly shorter OS and freedom from disease progression.

To further clarify the impact of *SOCS1* mutations in NHL, Schif *et al*([2013](#bjh16147-bib-0028){ref-type="ref"}) showed an inverted effect of *SOCS1* mutations in a historical cohort of 154 majoritarian CHOP‐treated DLBCL patients. In contrast to the other lymphoma entities, mutations resulting in severe changes to the *SOCS1* protein led to good outcomes compared to patients harbouring tumours with wildtype *SOCS1*. Paradoxically, minor mutations in *SOCS1* were found in tumour tissue of patients with the shortest OS, which was even shorter than the *SOCS1* wildtype group.

In a recent study, the *SOCS1* mutation effects were examined in an independent cohort of DLBCL patients (Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}). A group of 21/76 R‐CHOP‐treated DLBCL patients was shown to have mutations in the *SOCS1* gene. Only parts of the results of the initial study could be confirmed. Juskevicius *et al*([2017](#bjh16147-bib-0009){ref-type="ref"}) also showed that *SOCS1* mutations led to longer progression‐free survival (PFS) in this cohort, but no differences were seen between major and minor mutations, indicating that the negative effects of minor mutations are unimportant for the patients' survival in this cohort.

We tested a homogeneous cohort of elderly DLBCL patients \[RICOVER‐60 trial (Pfreundschuh *et al*, [2008](#bjh16147-bib-0020){ref-type="ref"})\] treated with the CHOP regimen, either with or without additional rituximab treatment, in order to ascertain whether the impact of *SOCS1* mutations in DLBCL in CHOP‐treated patients could be confirmed and whether the addition of rituximab affected the impact of *SOCS1* mutations as a prognosticator.

Methods {#bjh16147-sec-0002}
=======

Patients' data {#bjh16147-sec-0003}
--------------

The DLBCL patients in this study belonged to the rituximab‐with‐CHOP‐over‐age‐60 years trial (RICOVER‐60; DSHNHL 1999‐1A) (Pfreundschuh *et al*, [2008](#bjh16147-bib-0020){ref-type="ref"}). The patients were treated with 6 or 8 cycles of the CHOP‐14 treatment regimen either with or without 8 cycles of rituximab (CHOP vs. R‐CHOP). Follow‐up data included event‐free (EFS), progression‐free (PFS), and OS together with rates of response and frequencies of toxicity. The study was carried out in compliance with the Helsinki declaration and confirmed by the Ethics Committees of the participating centres. The examination of the *SOCS1* mutation status and correlation to the patients' data was confirmed by a separate ethics vote. Patient characteristics, immunohistochemical and fluorescence in situ hybridization data were collected as described previously (Pfreundschuh *et al*, [2008](#bjh16147-bib-0020){ref-type="ref"}; Ott *et al*, [2010](#bjh16147-bib-0019){ref-type="ref"}; Staiger *et al*, [2017](#bjh16147-bib-0031){ref-type="ref"}).

*SOCS1* sequencing {#bjh16147-sec-0004}
------------------

To deal with to the high fragmentation of DNA isolated from formalin‐fixed and paraffin‐embedded (FFPE) material, the open reading frame of *SOCS1* was examined using primer pairs amplifying overlapping amplicons of 177--360 bp (see Figure [S1](#bjh16147-sup-0001){ref-type="supplementary-material"}, Table [SI](#bjh16147-sup-0001){ref-type="supplementary-material"}). Sanger sequencing was performed, and the data were analysed using the Seqscape 2.5 software (Applied Biosystems, Foster City, CA, USA). The limit of mutation detection was set to 25%. All sequences were checked manually in order to identify insertions or deletions.

###### 

*SOCS1* mutation status and grouping of the DLBCL patients of the RICOVER‐60 sub‐cohort. Grouping of the patients with respect to the *OCS1* mutation status, three different classifiers and the treatment with or without rituximab.

  *SOCS1* status                                   Classifier (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"})   Classifier (Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"})   Novel classifier      CHOP‐treated (*n* = 136)   R‐CHOP‐treated (*n* = 130)   Total (*n* = 266)
  ------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------------ --------------------- -------------------------- ---------------------------- -------------------
  Wildtype                                         Wildtype                                                                 Wildtype                                                                       Putative neutral      90 (66%)                   91(70%)                      181 (68%)
  Silent mutations                                                                                                                                                                                                               9 (7%)                     11 (9%)                      20 (8%)
  Point mutations (tolerated)                      minor mutations                                                          mutated                                                                                              16 (12%)                   11 (9%)                      27 (10%)
  Point mutations (damaging)                                                                                                                                                                               putative pathogenic   13 (10%)                   8 (6%)                       21 (8%)
  Indels (in frame)                                major mutations                                                                                                                                                               3 (2%)                     0 (0%)                       3 (1%)
  Indels (out of frame) or premature stop codons                                                                                                                                                                                 5 (4%)                     9 (7%)                       14 (5%)
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Classification of mutations {#bjh16147-sec-0005}
---------------------------

We used three separate mutations classification schemes: (i) We distinguished between *SOCS1* mutant and wildtype mutations; (ii) We used a distinction of *SOCS1* major, minor, and wildtype mutations following prior definitions (minor = non‐length altering) and major (indels and/or truncating mutations) (Lennerz *et al*, [2015](#bjh16147-bib-0011){ref-type="ref"}); (iii) The impact of point mutations on the protein function was also estimated using a composite prediction composed of polyphen‐2 (Adzhubei *et al*, [2010](#bjh16147-bib-0001){ref-type="ref"}), Fathmm (Shihab *et al*, [2013](#bjh16147-bib-0029){ref-type="ref"}), Provean (Choi *et al*, [2012](#bjh16147-bib-0006){ref-type="ref"}), SIFT (Sim *et al*, [2012](#bjh16147-bib-0030){ref-type="ref"}), Panther (Mi *et al*, [2013](#bjh16147-bib-0015){ref-type="ref"}) and SusPect (Yates *et al*, [2014](#bjh16147-bib-0034){ref-type="ref"}). Briefly, the results were scored ranging from 0 (=predicted neutral) to predicted pathogenic (1) and a z score was calculated as the arithmetic mean across the six individual prediction scores. A *z* score of \<0·5 was ranked as a predicted neutral, whereas a score of \>0·7 was ranked as a predicted pathogenic mutation. In the cases with a score between 0·5 and 0·7, the mutation was tested using the Meta‐SNP prediction tool (Capriotti *et al*, [2013](#bjh16147-bib-0005){ref-type="ref"}) for a final classification. Specifically, for the third classification, patients harbouring at least one putative pathogenic *SOCS1* mutations were combined with those patients harbouring insertions, deletions or premature stop codons and are referred to collectively as "putative pathogenic"; the remaining patients (putative neutral *SOCS1* mutations and wildtype) were grouped and we refer to these as "putative neutral".

Statistical analysis {#bjh16147-sec-0006}
--------------------

Event‐free survival (events: progression, start of salvage treatment, additional (unplanned) treatment, relapse or death from any cause), PFS (events: progression, relapse or death from any cause), and OS (event: death from any cause) were measured from the time of randomization. EFS, PFS and OS were estimated according to the Kaplan--Meier method and log‐rank tests were performed. Multivariate Cox regression models for *SOCS1* results were adjusted for the factors of the International Prognostic Index (IPI, factors: age \>60 years, lactate dehydrogenase \>N, EAStern Cooperative Oncology Group performance status \>1, Stage III/IV, extranodal involvement \>1). Hazard ratios (HRs) with 95% confidence intervals (CIs) and *P*‐values are presented. For the correlation of *SOCS1* results with qualitative data (morphology, immunohistochemistry, fluorescence *in situ* hybridisation and Lymph2Cx data) and for differences regarding patient characteristics, we used chi‐square and Fisher's exact test. The two‐sided significance level was *P* \< 0·05. No *P*‐value correction for multiple tests were done due to the explorative character of the analyses. Statistical analyses were performed using SPSS Statistics 23 (IBM Corp., Armonk, NY, USA).

Re‐evaluation of published next generation sequencing data {#bjh16147-sec-0007}
----------------------------------------------------------

To validate our findings, published exome and transcriptome data and OS of 1001 DLBCL patients (Reddy *et al*, [2017](#bjh16147-bib-0022){ref-type="ref"}) were re‐evaluated with respect to *SOCS1* mutation status. After the exclusion of patients with missing data (*SOCS1* mutation status, OS), *SOCS1* mutations were classified as described earlier. Survival curves and statistics (Log‐rank tests) were carried out using the Prism software (GraphPad Software Inc., San Diego, CA, USA).

Results {#bjh16147-sec-0008}
=======

Evaluable subgroup of the patients represents the whole RICOVER‐60 cohort {#bjh16147-sec-0009}
-------------------------------------------------------------------------

About 30% (266 of an initial 949 patients with confirmed reference diagnosis of DLBCL) of the DLBCL patients of the cohort could be examined. This reduced number was due to the availability of remaining tumour tissue and the grade of DNA degradation within the samples and fits to novel data of *TP53* mutations within this cohort (Zenz *et al*, [2017](#bjh16147-bib-0035){ref-type="ref"}).

We tested for differences in EFS, PFS (PFS) and OS between the cases with or without *SOCS1* mutation data. No significant differences were found, either in the total group or after splitting into treatment‐based sub‐groups (Figure [S2](#bjh16147-sup-0001){ref-type="supplementary-material"}). This was also true for the gender distribution (with: 143 males (54%): 123 females (46%) and without: 368 males (54%): 315 femails (46%), respectively; *P* = 0·973) and the median of the patients' age (with: 68 years \[61--80\] *versus* without: 69 \[61--80\]; *P* = 0·436). No clinically relevant difference for the distribution of the IPI score between patients with *SOCS1* mutation data and the whole RICOVER‐60 cohort were observed (IPI 1, 2, 3, 4--5: 39, 25, 25, 11% and 32, 27, 25, 16%, respectively). Therefore, the subgroup of 266 patients investigated is representative of the total of 949 patients of the cohort.

*SOCS1* mutations in the Ricover‐60 cohort {#bjh16147-sec-0010}
------------------------------------------

Mutations in the *SOCS1* gene were detected by polymerase chain reaction (PCR) amplification of the open reading frame followed by Sanger sequencing of the amplicons. Eighty‐five of the 266 (32%) patient DNAs showed aberrations compared to the reference *SOCS1* sequence. Exclusively silent single nucleotide exchanges were detected in 20 of 266 (8%) and single nucleotide polymorphisms resulting in amino acid changes were found in 48/266 (18%) of the patient DNAs examined. Mutations affecting the length of the resulting *SOCS1* protein caused by insertions, deletions or premature stop codons were seen in 17/266 (6%) patients. Therefore, the frequency of non‐silent *SOCS1* mutations in the RICOVER‐60 cohort is 24%. *SOCS1* single nucleotide exchanges found in the RICOVER‐60 cohort were distributed throughout the entire open reading frame in a homogeneous manner (Fig [1](#bjh16147-fig-0001){ref-type="fig"}A). Therefore, no mutation hotspots could be identified. We point out that the lack of hotspots defers specifically to a lack of recurrent positional accumulation across cases, which we confirmed by comparison with publicly available data across different cancer types (Figure [S3](#bjh16147-sup-0001){ref-type="supplementary-material"}). In contrast, we acknowledge that there is an accumulation of *SOCS1* variants in nucleotide motifs that follow the somatic hypermutation motifs RGYW/WRCY, DGYW/WRCH and WA/TW (Mottok *et al*, [2009](#bjh16147-bib-0016){ref-type="ref"}). The patients were grouped using different mutation classifiers with respect to the preceding studies ([1](#bjh16147-tbl-0001){ref-type="table"}).

![Distribution and location of *SOCS1* mutations found in the patient DNA of the RICOVER‐60 cohort. (A) Distribution of point mutations over the open reading frame of *SOCS1*. Silent mutations are presented in black, mutations resulting in amino acid changes are light grey. The total of all point mutations is shown as dark grey dots. Special domains of the *SOCS1* protein are displayed as coloured lines covering the corresponding base pairs (bp) as indicated. (B) Diagram of the *SOCS1* mutations (*n* = 17) affecting the length of the *SOCS1* protein. Diamonds indicate deletions. Circles indicate stop codons. Dotted lines mark changed sequences as a result of frameshifts. (C) Diagram of the location of amino acid changing point mutations throughout the *SOCS1* open reading frame with respect to the calculated impact on protein function (*z* score). Mutations predicted to affect the protein function are displayed in red. Mutations calculated to be neutral for the protein function are coloured in green. (D) Presentation of the point mutations with respect to the functional domains of the *SOCS1* protein as percentages. White bars show the allocation of the base pairs attributed to the domain groups "N‐terminus, KIR and ESS domain" and "SH2 domain and SOCS box", to clarify if the mutation distributions are due to the different numbers of base pairs within the groups. Grey bars represent silent mutations. Green bars illustrate mutations calculated not to affect the protein function (putative neutral). There were no differences compared to the number of base pairs within the two groups, suggesting a random occurrence of the mutations. Red bars give the distribution of mutations affecting the function of the *SOCS1* protein. These mutations were almost exclusively found in the SH2 domain and the SOCS‐box.](BJH-187-627-g001){#bjh16147-fig-0001}

For comparison of the results with the first DLBCL study (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}), the patients were grouped as *SOCS1* wildtype (*n* = 201), *SOCS1* minor mutated (*n* = 48) and *SOCS1* major mutated patients (*n* = 17) and split into CHOP‐ (*n* = 136) and R‐CHOP (*n* = 130) subgroups to reduce bias provoked by the treatment. To compare the results with the second DLBCL study (Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}), the patients were grouped into *SOCS1* wildtype (*n* = 201) and *SOCS1* mutated patients (*n* = 65). Additionally, the prediction of the severity of mutational impact on the function of the *SOCS1* protein was used as a novel classifier, resulting in patients with putative neutral (*n* = 228, wildtype *SOCS1* included) and putative pathogenic (*n* = 38) *SOCS1* mutations. About 37% of the base pairs of the *SOCS1* open reading frame can be assigned to the N‐terminus, the KIR and the ESS domain, whereas about 63% refer to the SH2 domain and the SOCS box. Silent mutations found in the N‐terminus, the KIR and the ESS domain account for 36%, leaving 64% of the silent mutations located in the SH2 domain and SOCS box. The distribution of putative neutral mutations was comparable (41% and 59% respectively). Therefore, silent and putative neutral mutations were found to be distributed randomly throughout the entire open reading frame. Interestingly, the putative pathogenic point mutations were mainly located in the SH2 domain and the SOCS box of the *SOCS1* protein (97%; Fig [1](#bjh16147-fig-0001){ref-type="fig"}C,D). Deletions and point mutations causing premature stop codons affect the SH2 domain or the SOCS box in 14/17 (82%) of cases (Fig [1](#bjh16147-fig-0001){ref-type="fig"}B), highlighting the importance of these domains for the protein's function. Comparing patient characteristics, IHC and FISH data with regard to the differing classifiers of *SOCS1* mutations, no striking differences or correlations were detected (Table [SII](#bjh16147-sup-0001){ref-type="supplementary-material"}).

The paradoxical effect on patients' survival of minor and major *SOCS1* mutations in CHOP‐treated DLBCL cannot be confirmed {#bjh16147-sec-0011}
---------------------------------------------------------------------------------------------------------------------------

The initial *SOCS1* study on DLBCL revealed a paradoxical effect of minor and major *SOCS1* mutations compared to cHL cases (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}). To elucidate whether the results of this study of *SOCS1* mutation effects in DLBCL could be confirmed, the cases of the novel cohort were grouped into *SOCS1* wildtype, *SOCS1* minor mutation and *SOCS1* major mutation cases. Comparable classification standards were used as reported by Schif *et al*([2013](#bjh16147-bib-0028){ref-type="ref"}). No significant differences were detected in EFS, PFS or OS of the groups in the corresponding group of CHOP‐treated DLBCL patients (*n* = 136; Figure [S4](#bjh16147-sup-0001){ref-type="supplementary-material"}B). The same results were observed in the R‐CHOP‐treated patients (*n* = 130; Figure [S4](#bjh16147-sup-0001){ref-type="supplementary-material"}C) and the total number of patients (*n* = 266; Figure [S4](#bjh16147-sup-0001){ref-type="supplementary-material"}A). Therefore, the finding that minor *SOCS1* mutations lead to reduced survival times compared to major mutations in DLBCL patients was not confirmed in this DLBCL trial, also after adjusting for IPI factors in multivariate Cox regression models.

The uniform positive effect on patients' outcome of mutated *SOCS1* in R‐CHOP‐treated DLBCL cannot be confirmed {#bjh16147-sec-0012}
---------------------------------------------------------------------------------------------------------------

A recent study on mutations in DLBCL indicated a uniform positive effect of *SOCS1* mutations regardless of a sub‐classification of the mutations (Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}). To test if these positive effects of mutated *SOCS1* in R‐CHOP‐treated DLBCL patients could be confirmed, all mutated cases (except silent mutations) were grouped together and tested for differences in EFS, PFS and OS against the group with wildtype *SOCS1*. Among the patients treated with R‐CHOP (the corresponding comparison group to the recent *SOCS1* mutation study), no significant differences were found (*P* = 0·573; *P* = 0·790; *P* = 0·521; Figure [S5](#bjh16147-sup-0001){ref-type="supplementary-material"}C). Comparable results were observed for the CHOP‐treated patients (*P* = 0·114; *P* = 0·230; *P* = 0·595; Figure [S5](#bjh16147-sup-0001){ref-type="supplementary-material"}B) and the total number of patients (*P* = 0·473; *P* = 0·588; *P* = 0·937; Figure [S5](#bjh16147-sup-0001){ref-type="supplementary-material"}A). Therefore, the results of this recently published cohort were also not confirmed by this trial, also after adjusting for IPI factors in multivariate Cox regression model.

*SOCS1* mutations predicted to have negative impact on protein function are associated with shorter overall survival {#bjh16147-sec-0013}
--------------------------------------------------------------------------------------------------------------------

Regarding several published data stating that *SOCS1* mutation effects are dependent on the type of mutation (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}; Lennerz *et al*, [2015](#bjh16147-bib-0011){ref-type="ref"}), we tested the nucleotide changes with respect to the severity of their impact on protein function using different protein prediction tools. Using this refined method, the patients were divided into patients harbouring tumours with putative regular (wildtype *SOCS1* and neutral *SOCS1* mutations) or putative pathogenic *SOCS1* protein. Using this new classifier, we tested for differences in EFS, PFS and OS in a total of 266 patients and for the treatment‐adjusted subgroups. Although no differences could be observed in the total number of patients or in the CHOP‐treated group, we found a significantly shorter OS in patients with putative pathogenic *SOCS1* mutations treated with the R‐CHOP regimen (*P* = 0·037; Fig [2](#bjh16147-fig-0002){ref-type="fig"}). In a multivariate Cox regression model adjusted for IPI factors, these results were confirmed with a HR of 1·9 (95% CI (0·9--4·2); however, these differences did not reach significance (*P* = 0·105). The reduced survival in elderly patients with putative pathogenic *SOCS1* mutations may be a consequence of the known and superimposed strong prognostic effects of higher IPI stages. Nonetheless, after adjustment for the IPI factors and cell of origin ABC vs. GCB subtype (Lymph2Cx), a significant hazard ratio in R‐CHOP treated patients with putative pathogenic *SOCS1* mutations (HR = 2·8 95% CI (1·0--7·4) *P* = 0·042) was observed for OS.

![Survival of DLBCL patients related to the predicted effect of *SOCS1* mutations. The survival time analyses of the patients of the RICOVER‐60 trial are shown with putative neutral (green) or putative pathogenic (red) *SOCS1* with respect to all cases (left panel) or patient treatments \[middle panel: CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisolone)‐treated; right panel: R‐CHOP (CHOP + rituximab)‐treated\]. The analyses were calculated for event‐free survival (EFS), progression‐free survival (PFS) and overall survival (OS). Patients harbouring putative pathogenic *SOCS1* mutations show a significantly shorter overall survival (*P* = 0·037). Abbreviations: *n*, numbers of patients; *P*, *P*‐value from log‐rank test.](BJH-187-627-g002){#bjh16147-fig-0002}

Younger age at diagnosis and putative pathogenic *SOCS1* mutations as prediction of pre‐eminent survival {#bjh16147-sec-0014}
--------------------------------------------------------------------------------------------------------

We conducted a re‐evaluation of a large fourth cohort of published and online available sequencing data (Reddy *et al*, [2017](#bjh16147-bib-0022){ref-type="ref"}) of DLBCL patients with respect to the *SOCS1* mutation status, to validate the prognostic associations. No differences in OS were seen comparing patients by *SOCS1* mutation status (*n* = 91 vs. *SOCS1* wildtype *n* = 871, Fig [3](#bjh16147-fig-0003){ref-type="fig"}A). Classifying the *SOCS1* mutations into minor and major mutations revealed that patients with major mutations tended to have longer OS compared to patients with minor mutations or wildtype *SOCS1*. However, these differences were not significant (*P* = 0·153). The same was shown by classifying into putative neutral or putative pathogenic *SOCS1* mutations (Fig [3](#bjh16147-fig-0003){ref-type="fig"}B,C). As the patients of the RICOVER‐60 cohort were uniformly elderly patients aged over 60 years, we excluded the patients younger than 60 years from the cohort reported by Reddy *et al*([2017](#bjh16147-bib-0022){ref-type="ref"}). In these age‐based subsets we did not see differences in OS in the remaining subgroup of elderly patients; neither by *SOCS1* mutation status, nor by using the other *SOCS1* classifiers (Fig [3](#bjh16147-fig-0003){ref-type="fig"}D--F). Examination in the subgroup of patients younger than 60 years at diagnosis showed a trend for a longer OS regarding all *SOCS1* mutations and for major mutations compared to the corresponding subgroup of patients with *SOCS1* wildtype (*P* = 0·197 and *P* = 0·072). The novel classifier (putative neutral and putative pathogenic *SOCS1*) revealed a significant difference in OS in this subgroup of younger patients (under 60 years of age at diagnosis, Fig [3](#bjh16147-fig-0003){ref-type="fig"}G--I; *P* = 0·014).

![Re‐evaluation of publicly available sequence and survival data of DLBCL patients (Reddy et al, [2017](#bjh16147-bib-0022){ref-type="ref"}). Overall survival of patients with mutated *SOCS1* and *SOCS1* wildtype. A, B, C: total evaluable patient data (*n* = 962); D, E, F: patients aged over 60 years (60y) at diagnosis (*n* = 558); G, H, I: patients aged under 60 y at diagnosis (*n* = 404). Comparisons were illustrated either as *SOCS1* wildtype *versus* mutated *SOCS1* (A,D,G), *SOCS1* wildtype *versus SOCS1* major and/or minor mutations (B, E, H), and putative neutral *SOCS1 versus* putative pathogenic *SOCS1* (C, F, I). *P*‐values represent log rank tests (Mantel‐Cox) comparing 2 survival curves.](BJH-187-627-g003){#bjh16147-fig-0003}

Putative pathogenic *SOCS1* mutations stall the benefit of Rituximab on overall survival of DLBCL patients {#bjh16147-sec-0015}
----------------------------------------------------------------------------------------------------------

Knowing that harbouring a pathogenic *SOCS1* mutation is associated with shorter OS, we compared the EFS, PFS and OS of patients with putative regular *SOCS1* protein treated with or without rituximab. The same comparison was made for patients with putative pathogenic *SOCS1* proteins. Log rank tests showed that the R‐CHOP‐treated patients with putative regular *SOCS1* protein had significant differences in EFS and PFS and showed a trend to longer OS (*P* = 0·045, *P* = 0·011, and *P* = 0·088) compared to the corresponding CHOP‐treated patients. No significant differences were seen when comparing the patients with putative pathogenic *SOCS1* with respect to rituximab treatment (*P* = 0·863, *P* = 0·884, *P* = 0·611). Therefore, it seems that *SOCS1* pathogenic mutations stall the benefit gained by rituximab treatment (Fig [4](#bjh16147-fig-0004){ref-type="fig"}) in elderly patients. These results were confirmed in multivariate Cox regression models for rituximab‐containing treatment adjusted for IPI factors (within putative neutral: HR~EFS~ = 0·7 (95%CI: 0·4--1·0) *P* = 0·028, HR~PFS~ = 0·6 (95%CI: 0·4--0·8) *P* = 0·004, HR~OS~ = 0·7 (95%CI: 0·4--1·0) *P* = 0·053; within putative pathogenic: HR~EFS~ = 1·2 (95%CI: 0·4--3·1) *P* = 0·749, HR~PFS~ = 1·2 (95%CI: 0·4--3·3) *P* = 0·723, HR~OS~ = 2·2 (95%CI: 0·7--6·5) *P* = 0·156). This supports the hypothesis that putative pathogenic *SOCS1* mutations counteract the beneficial effect of a rituximab treatment.

![Putative pathogenic *SOCS1* mutations distinguish rituximab responder and non‐responder. The survival curves for the DLBCL subgroups of patients with putative regular *SOCS1* treated with rituximab (red line), patients with putative neutral *SOCS1* treated without rituximab (blue line), patients with putative pathogenic *SOCS1* treated with rituximab (green line) and without rituximab (orange line) are shown for event‐free (EFS), progression‐free (PFS) and overall survival (OS). *P*‐values indicate the results of log ranks tests. CHOP: cyclophosphamide, hydroxydaunorubicin, vincristine, prednisolone; R‐CHOP: CHOP + rituximab.](BJH-187-627-g004){#bjh16147-fig-0004}
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==========

Here, we report results of a large‐scale assessment of *SOCS1* genotyping as a prognostic biomarker in a large cohort of clinically well‐annotated DLBCL patients. We show that putative pathogenic *SOCS1* mutations seem to efface the beneficial effect of the therapeutic CD20 antibody, rituximab. We have validated these findings in an independent cohort and consider these findings important for several reasons. The functions of the *SOCS1* protein have been examined over the last two decades and a crucial role found in the cytokine signalling pathway mediated by JAKs and STAT proteins. As the relevance of mutations in *SOCS1* was clearly demonstrated for primary mediastinal B‐cell lymphoma (Barth *et al*, [2005](#bjh16147-bib-0003){ref-type="ref"}; Ritz *et al*, [2008](#bjh16147-bib-0024){ref-type="ref"}) and cHL (Weniger *et al*, [2006](#bjh16147-bib-0033){ref-type="ref"}; Lennerz *et al*, [2015](#bjh16147-bib-0011){ref-type="ref"}), findings concerning the role of mutated *SOCS1* in DLBCL were controversial (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}; Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}). Our first study of a DLBCL cohort (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}) revealed that subgrouping, of major and minor mutated *SOCS1,* which had previously been seen in cHL patients, can also be found in DLBCL patients. But the impact of the mutations seemed to be inverted compared to the impact found in cHL. While major *SOCS1* mutations in cHL were a prognostic factor for shorter survival, in DLBCL major mutations paradoxically predicted an extremely good outcome. DLBCL patients with minor *SOCS1* mutations were predicted to have extremely short survival times. The results of the second study (Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}) confirm that *SOCS1* mutations in DLBCL may be used to predict a better outcome, at least for PFS in these patients. But here, the devastating effect of minor *SOCS1* mutations was not seen at all. To clarify the situation, we embarked to verify the data in a cohort that not only reflects both studies but also overcomes some of the limitations of the previous studies. To overcome the limitation of low patient numbers, 266 samples of the RICOVER‐60 trial were shown to be representative of the 949 confirmed DLBCL patients of the whole study. All patients of this prospective and randomized cohort were elderly, aged between 61 and 80 years, eliminating the issue of extreme age variability of onset of the disease in the other studies. The age of the majority (*n* = 154) of the CHOP‐treated patients in the study reported by Schif *et al*([2013](#bjh16147-bib-0028){ref-type="ref"}), as well as the age of the 76 R‐CHOP‐treated patients of the study reported by Juskevicius *et al*([2017](#bjh16147-bib-0009){ref-type="ref"}), was extremely heterogeneous, ranging from 3 to 93 years in the first and 18 to 81 years in the latter, which is a confounder on its own (Klapper *et al*, [2012](#bjh16147-bib-0010){ref-type="ref"}). As the patients' treatment may be a relevant factor for the differing impact of *SOCS1* mutations, it is a great benefit of the RICOVER‐60 trial that it includes both CHOP‐ and R‐CHOP‐treated patients. The mutation frequency of *SOCS1* in our cohort is 24% (65/266) and is hereby in between the frequencies determined in former studies (16% and 28%, respectively).

In general, we have to state that our results do not confirm those of either Schif *et al*([2013](#bjh16147-bib-0028){ref-type="ref"}) or Juskevicius *et al*([2017](#bjh16147-bib-0009){ref-type="ref"}). This may be for different reasons: patient age, non‐uniformity of treatment in the cohort reported by Schif *et al*([2013](#bjh16147-bib-0028){ref-type="ref"}) and probably a technical reason because two patients of their cohort with no further mutations than silent mutations in *SOCS1* were grouped as minor mutations. Nevertheless, we could establish that mutations affecting protein function (putative pathogenic *SOCS1*) can be used to predict a significantly shorter OS in R‐CHOP‐treated elderly DLBCL patients. This corresponds to mutated *SOCS1* effects seen in PMBL and cHL. Additionally, we found that putative pathogenic *SOCS1* mutations might predict whether a DLBCL patient benefits from additional rituximab treatment given in elderly patients. Comparing our results of CHOP‐ vs. R‐CHOP treated patients, the hypothesis arises that the positive effect of rituximab on patient outcome is no longer noticeable in R‐CHOP‐treated patients with putative pathogenic mutations in *SOCS1*. Therapeutic CD20 antibodies act in different ways: (i), induction of non‐classical apoptosis by crosslinking multiple CD20 molecules, (ii), activation of complement‐dependent cytotoxicity, (iii), induction of cell‐mediated cytotoxicity, (iv), antigen signalling enhancement via FcγR crosslinking, or (v), complement‐enhanced antibody dependent cell‐mediated cytotoxicity \[reviewed in (Boross & Leusen, [2012](#bjh16147-bib-0004){ref-type="ref"})\]. The net effect of pathogenic mutations of *SOCS1* was shown to prolong the JAK‐STAT signals inducing proliferation in B lymphoma cells (Melzner *et al*, [2006](#bjh16147-bib-0014){ref-type="ref"}). A hypothetical bridge between these processes might be that tonic JAK‐STAT activity confers some kind of resistance to at least one of the rituximab effects. This is a topic to be investigated further in *in vitro* studies.

In order to validate our findings within an independent cohort of age‐mixed DLBCL patients with published whole exome and transcriptome data (Reddy *et al*, [2017](#bjh16147-bib-0022){ref-type="ref"}), we found that the inconsistent beneficial effects of *SOCS1* defect mutations are due to the broad range in the age at diagnosis of DLBCL patients in the studies published earlier (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}; Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}). Splitting these patients to subgroups with early and late onset of disease (age of diagnosis, \<60 and 60+ years, respectively), we clearly confirmed the beneficial *SOCS1* defect mutation effect described in the first two studies (Schif *et al*, [2013](#bjh16147-bib-0028){ref-type="ref"}; Juskevicius *et al*, [2017](#bjh16147-bib-0009){ref-type="ref"}) within the younger patients. Elderly patients did not show an altered survival related to *SOCS1* mutation status. This emerged as a trend when stratifying the mutations into minor and major. Using the novel classifiers (putative neutral and putative pathogenic *SOCS1* mutations) significantly enhanced this effect. Therefore, the initial concept of sub‐classifying the *SOCS1* mutations is useful in DLBCL as a classifier for the patients' outcome albeit in a more nuanced manner and is very likely to be especially useful for outcome prediction in early onset DLBCL patients.

In summary, the distinct role of *SOCS1* in DLBCL remains uncertain; three independent studies of differing cohorts failed to show a uniform effect of *SOCS1* mutations. Possibly, the effects of *SOCS1* mutations are partly superimposed by effects of other mutated genes. Nonetheless, the results of this study deliver the first data on elderly patients within a highly controlled prospective and randomized trial of DLBCL. Furthermore, it could be shown that the 266 patients analysed reflect the larger number of 949 DLBCL patients. The issue of patients undergoing differing treatments was overcome by having subgroups of the two main treatment regimens used in recent decades. This study is the first on *SOCS1* mutation effects in DLBCL patients revealing a comparable impact of *SOCS1* mutations as seen in PMBL or cHL. Nonetheless, it has to be noted that the shorter OS of R‐CHOP treated patients with putative pathogenic *SOCS1* mutations retained significance in the multivariate analysis against the stronger prognostic factor of IPI staging only after adjustment for IPI factors and cell of origin ABC vs. GCB subtype (Lymph2Cx). Furthermore, the inferior OS of elderly patients with putative pathogenic *SOCS1* mutations could not be confirmed in an independent cohort. It is conceivable that this *SOCS1* mutation effect is restricted to elderly patients treated with the R‐CHOP regimen.

Our analysis of the published next generation sequencing data (Reddy *et al*, [2017](#bjh16147-bib-0022){ref-type="ref"}), showed that the age of onset is a very important factor for consideration when using *SOCS1* mutations as a predictor for survival in DLBCL patients treated with CHOP, and R‐CHOP or other rituximab‐containing treatment schemes. Although further research has yet to be performed to consolidate this, the results of our study imply a difference between elderly DLBCL patients who benefit or not from rituximab treatment in addition to the classical CHOP therapy regime. The survey of four independent DLBCL studies implies that putative pathogenic *SOCS1* mutations may be used to forecast an extremely favourable OS of early onset DLBCL patients (aged \<60 years).
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